Cai You-Zhi, Nie Liu-Yan, Ruan Jia-Qi, Zhao Kun
Department of Orthopedics and Center for Sport Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Rheumatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; School of Medicine, Zhejiang University, Hangzhou, China.
Clin Ther. 2021 Dec;43(12):2116-2126. doi: 10.1016/j.clinthera.2021.10.011. Epub 2021 Nov 21.
Previous meta-analyses have reported the superiority of tanezumab versus placebo in the treatment of osteoarthritis (OA). However, they did not compare different injection methods (intravenous or subcutaneous), doses of injection.
The goal of this network meta-analysis (NMA) was to evaluate the therapeutic effects of different dosages and methods of injection of tanezumab on relieving pain in patients with OA.
An online systematic search was performed by using the PubMed, Cochrane Library, EMBASE, and ClinicalTrials.gov databases from inception to November 9, 2019. The goal was to identify randomized controlled trials (RCTs) that concentrated on the therapeutic effects of different dosages and methods of injection of tanezumab in patients with OA. The pairwise meta-analyses with the fixed effects model were undertaken with the "meta" package using R 3.6.0 programming language. In addition, an NMA with fixed effects was assessed using a gemtc software. The surface under the cumulative ranking curve value of each intervention was calculated to obtain a hierarchy of treatments.
Of the 328 RCTs identified through the literature search, 12 RCTs were included in the current NMA. In terms of the Western Ontario and McMaster Universities Osteoarthritis Index pain and physical function subscales, the most effective treatment was intravenous injection of tanezumab (10 mg; surface under the cumulative ranking curve values of 90% and 88%, respectively), and the least effective therapy was subcutaneous injection of tanezumab (2.5 mg; 20% and 19%).
To achieve high therapeutic efficacy and avoid treatment failure, an intravenous injection of tanezumab (10 mg) is recommended as an efficacious therapy, facilitating pain relief in patients with OA. However, this conclusion may also be affected by the limitations of this study owing to the small sample size and data heterogeneity, and further research should therefore be conducted to eliminate these limitations and to confirm the findings.
以往的荟萃分析报告了他尼珠单抗在治疗骨关节炎(OA)方面优于安慰剂。然而,这些分析并未比较不同的注射方法(静脉注射或皮下注射)及注射剂量。
本网状荟萃分析(NMA)的目的是评估他尼珠单抗不同剂量和注射方法对缓解OA患者疼痛的治疗效果。
通过使用PubMed、Cochrane图书馆、EMBASE和ClinicalTrials.gov数据库,从建库至2019年11月9日进行在线系统检索。目的是识别专注于他尼珠单抗不同剂量和注射方法对OA患者治疗效果的随机对照试验(RCT)。使用R 3.6.0编程语言,通过“meta”软件包进行固定效应模型的成对荟萃分析。此外,使用gemtc软件评估固定效应的NMA。计算每种干预措施的累积排名曲线下面积值,以获得治疗等级。
通过文献检索确定的328项RCT中,有12项RCT纳入了当前的NMA。就西安大略和麦克马斯特大学骨关节炎指数疼痛和身体功能分量表而言,最有效的治疗方法是静脉注射他尼珠单抗(10 mg;累积排名曲线下面积值分别为90%和88%),最无效的治疗方法是皮下注射他尼珠单抗(2.5 mg;20%和19%)。
为了获得高治疗效果并避免治疗失败,推荐静脉注射他尼珠单抗(10 mg)作为一种有效的治疗方法,有助于缓解OA患者的疼痛。然而,由于样本量小和数据异质性,该结论可能也受到本研究局限性的影响,因此应进行进一步研究以消除这些局限性并证实研究结果。